Overview
-
Welcome to Multibagg AI
Log in to access personalized features
Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
₹604.52
▼ 1.64
(0.27%)
| Instrument Name | Watchlist | Investment Date | % Holding | No of Units | Value (₹ Cr) | Asset Type | Industry Name |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical ... | 31 Aug 2026 | 12.33% | 36,00,000 | ₹714.53 Cr | Equity | Pharmaceuticals | |
 Divis Laboratories Ltd | 31 Aug 2026 | 8.17% | 5,00,000 | ₹473.35 Cr | Equity | Pharmaceuticals | |
 Apollo Hospitals En... | 31 Aug 2026 | 4.91% | 3,20,000 | ₹284.75 Cr | Equity | Healthcare | |
| Acutaas Chemicals Ltd | 31 Aug 2026 | 4.91% | 9,00,000 | ₹284.45 Cr | Equity | Pharmaceuticals | |
 Torrent Pharmaceuti... | 31 Aug 2026 | 4.72% | 5,40,000 | ₹273.56 Cr | Equity | Pharmaceuticals | |
 Cipla Ltd | 31 Aug 2026 | 4.67% | 19,20,000 | ₹270.57 Cr | Equity | Pharmaceuticals | |
 Max Healthcare Inst... | 31 Aug 2026 | 4.31% | 24,00,000 | ₹250.10 Cr | Equity | Healthcare | |
| TREPS | 31 Aug 2026 | 4.11% | 0 | ₹238.02 Cr | Reverse Repo | Debt Others | |
 Laurus Labs Ltd | 31 Aug 2026 | 3.96% | 12,00,000 | ₹229.80 Cr | Equity | Pharmaceuticals | |
| Aurobindo Pharma Ltd | 31 Aug 2026 | 3.90% | 13,18,192 | ₹226.33 Cr | Equity | Pharmaceuticals |
Funds in the same category by AUM
You can invest in SBI Healthcare Opportunities Fund - Direct (G) through a lump sum investment or a monthly SIP. The minimum lump sum investment is ₹5,000 and the minimum SIP amount is ₹500.
The latest NAV of SBI Healthcare Opportunities Fund - Direct (G) is ₹604.52.
SBI Healthcare Opportunities Fund - Direct (G) manages assets worth ₹5,796.42 Cr.
The expense ratio of SBI Healthcare Opportunities Fund - Direct (G) is 1.04%.
The exit load applicable on SBI Healthcare Opportunities Fund - Direct (G) is 0.50% - If redeemed/switched out wihin 15 days from the date of allotment. Nil - If redeemed/switched out after 15 days from the date of allotment..
As per the riskometer, SBI Healthcare Opportunities Fund - Direct (G) carries Very High risk.
SBI Healthcare Opportunities Fund - Direct (G) is managed by SBI Mutual Fund.
SBI Healthcare Opportunities Fund - Direct (G) belongs to the Sectoral Fund category.
SBI Healthcare Opportunities Fund - Direct (G) is benchmarked against the BSE Healthcare TRI.
SBI Healthcare Opportunities Fund - Direct (G) has no lock-in period, so units can be redeemed at any time subject to the applicable exit load.
SBI Healthcare Opportunities Fund - Direct (G) was launched on 02 Jan 2013.
After the initial investment, you can invest in SBI Healthcare Opportunities Fund - Direct (G) in further multiples of ₹1,000.
To provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
To provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
02 Jan 2013
₹5,796.42 Cr
₹604.52
₹500
₹5,000
Very High
1.04%
17.41
0.64
1.27
4.16
0.58
0.14
0.36
This fund has Very High risk.
Returns over a year are annualised (per year, compounded).
Calendar year return from the first period shown through each year.
| Company | Watchlist | Sector | Activity | Investment Date | % Holding | Market Value | Shares | Asset Type | Rating |
|---|---|---|---|---|---|---|---|---|---|
| Lupin Ltd | Pharmaceuticals -... | Sold | 31 Jul 2026 | 1.79% | ₹96.60 Cr | 4,00,000 | Equity | EQUITY | |
| Syngene Internation... | Miscellaneous - L... | Bought | 31 Jul 2026 | 0.96% | ₹51.58 Cr | 13,36,533 | Equity | EQUITY | |
 Healthcare Global E... | Hospitals / Medic... | Bought | 31 Jul 2026 | 0.73% | ₹39.53 Cr | 5,88,982 | Equity | EQUITY | |
| Lonza Group | — | Sold | 30 Jun 2026 | 2.04% | ₹102.17 Cr | 1,60,000 | Foreign Equity | UR / N.A. |
| Fund | 1Y | 3Y | Expense Ratio | Fund Size | Alpha | Sharpe | Risk | |
|---|---|---|---|---|---|---|---|---|
 Nippon India Pharma Fund - Di... | 13.21% | 19.75% | 0.99% | ₹9,479.08 Cr | 13.17 | 0.95 | Very High | |
| SBI Healthcare Opportunities ... | 22.78% | 24.99% | 1.04% | ₹5,796.42 Cr | 17.41 | 1.27 | Very High | |
 Mirae Asset Healthcare Fund -... | 22.11% | 24.02% | 0.61% | ₹3,555.18 Cr | 16.80 | 1.10 | Very High | |
 HDFC Pharma and Healthcare Fu... | 28.36% | — | 1.08% | ₹3,310.64 Cr | 24.17 | 1.58 | Very High | |
 UTI-Healthcare Fund - Direct (G) | 18.79% | 25.04% | 1.26% | ₹1,443.57 Cr | 17.68 | 1.17 | Very High | |
 Aditya Birla SL Pharma & Heal... | 19.32% | 22.43% | 1.02% | ₹1,102.73 Cr | 16.00 | 1.10 | Very High | |
 WhiteOak Capital Pharma and H... | 24.81% | — | 1.13% | ₹902.24 Cr | 19.86 | 1.14 | Very High |
Funds in the same category by AUM
| Fund | Watchlist | AMC | NAV | Fund Size | Expense Ratio | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|
 ICICI Pru Technology Fund... | ICICI Prudential Mutual Fund | ₹194.12 | ₹13,660.98 Cr | 1.22% | -11.08% | 4.46% | 1.93% | |
| HDFC Defence Fund - Direc... | HDFC Mutual Fund | ₹31.08 | ₹11,477.59 Cr | 0.89% | 23.83% | 38.03% | — | |
| ICICI Pru Banking & Finan... | ICICI Prudential Mutual Fund | ₹145.07 | ₹11,330.58 Cr | 1.23% | -3.67% | 9.21% | 8.98% | |
| SBI Banking & Financial S... | SBI Mutual Fund | ₹47.70 | ₹10,872.95 Cr | 1.20% | -0.70% | 14.93% | 11.76% | |
 Tata Digital India Fund -... | Tata Mutual Fund | ₹46.47 | ₹10,322.02 Cr | 0.67% | -13.66% | 3.50% | 1.77% | |
| SBI Healthcare Opportunit... | SBI Mutual Fund | ₹604.52 | ₹5,796.42 Cr | 1.04% | 22.78% | 24.99% | 18.70% |